Multiple redox switches of the SARS-CoV-2 main protease in vitro provide opportunities for drug design

Besides vaccines, the development of antiviral drugs targeting SARS-CoV-2 is critical for preventing future COVID outbreaks. The SARS-CoV-2 main protease (Mpro), a cysteine protease with essential functions in viral replication, has been validated as an effective drug target. Here, we show that Mpro is subject to redox regulation in vitro and reversibly switches between the enzymatically active dimer and the functionally dormant monomer through redox modifications of cysteine residues. These include a disulfide-dithiol switch between the catalytic cysteine C145 and cysteine C117, and generation of an allosteric cysteine-lysine-cysteine SONOS bridge that is required for structural stability under oxidative stress conditions, such as those exerted by the innate immune system. We identify homo- and heterobifunctional reagents that mimic the redox switching and inhibit Mpro activity. The discovered redox switches are conserved in main proteases from other coronaviruses, e.g. MERS-CoV and SARS-CoV, indicating their potential as common druggable sites.


Reporting Summary
Nature Portfolio wishes to to improve the reproducibility of of the work that we we publish.This form provides structure for consistency and transparency in in reporting.For further information on on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist Statistics For all statistical analyses, confirm that the following items are present in in the figure legend, table legend, main text, or or Methods section.

n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as as a discrete number and unit of of measurement A statement on on whether measurements were taken from distinct samples or or whether the same sample was measured repeatedly The statistical test(s) used AND whether they are one-or or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.

A description of of all covariates tested
A description of of any assumptions or or corrections, such as as tests of of normality and adjustment for multiple comparisons A full description of of the statistical parameters including central tendency (e.g.means) or or other basic estimates (e.g.regression coefficient) AND variation (e.g. standard deviation) or or associated estimates of of uncertainty (e.g.confidence intervals) For null hypothesis testing, the test statistic (e.g.F, t, r) with confidence intervals, effect sizes, degrees of of freedom and P value noted Give P values as exact values whenever suitable.
For Bayesian analysis, information on on the choice of of priors and Markov chain Monte Carlo settings For hierarchical and complex designs, identification of of the appropriate level for tests and full reporting of of outcomes Estimates of of effect sizes (e.g.Cohen's d, Pearson's r), ), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.

Software and code
Policy information about availability of of computer code

Data analysis
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers.We strongly encourage code deposition in a community repository (e.g.GitHub).See the Nature Portfolio guidelines for submitting code & software for further information.

Data Policy information about availability of data
All manuscripts must include a data availability statement.This statement should provide the following information, where applicable: -Accession codes, unique identifiers, or web links for publicly available datasets -A description of any restrictions on data availability -For clinical datasets or third party data, please ensure that the statement adheres to our policy analysis Chirascan Spectrometer Control Panel Application version 4.2.27 (Circular Dichroism) Spectra Manager version 2.07.02 (Build 4) 4) (UV-Vis-based Kinetics) X-ray crystallography mxCuBE 2 (X-ray data collection at at P14 DESY/EMBL, Hamburg, Germany) Mass spectrometry Fusion Lumos Tune 3.4.3072.18Xcalibur 4.4.16.14 Foundation 3.1 SP7QF1 build 306, SII 1.5 (all Thermo Fisher Scientific) Analytical ultracentrifugation ProteomeLab XL-I, GUI 6.0 (Firmware 5.7) Electronic structure calculations Gaussian16-A.03nature portfolio | reporting summary April 2023

Materials
calculation was performed, all biophysical experiments were conducted with three statistical replicates no data were excluded from analysis Experiments were performed in at least two independent biological replicates given virtually identical results n.a. as all data were included in the statistical analysis n.a.as all data were included in the statistical analysis 1. SARS-CoV-2 Spike (GeneTex, Cat# 632604) 2. SARS-CoV-2 Nucleoprotein (Sino Biological, Cat# 40143-R019) 3. GAPDH (abcam, Cat# ab8245) 4. Alexa Fluor 488 donkey anti-mouse (Thermo Fisher Scientific, Cat# A21202) 5. Alexa Fluor 546 donkey anti-rabbit (Thermo Fisher Scientific, Cat# A10040) 6. Donkey anti-mouse IgG, HRP conj.(JacksonImmunoResearch, Cat#715036150) Please select the one below that is the best fit for your research.If you are not sure, read the appropriate sections before making your selection.For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdfLifesciencesstudydesignAll studies must disclose on these points even when the disclosure is negative.We require information from authors about some types of materials, experimental systems and methods used in many studies.Here, indicate whether each material, system or method listed is relevant to your study.If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.